TG Therapeutics Inc., of New York, and Jiangsu Hengrui Medicine Co. Ltd., of Shanghai, entered an exclusive global license deal in which TG will obtain worldwide rights, excluding Asia but including Japan, to develop Hengrui’s Bruton’s tyrosine kinase inhibitor program.